REVIEW ARTICLE

비뇨기암에서 림프절 절제술과 림프부종

박사현1, 정재영1,*
Sahyun Pak1, Jae Young Joung1,*
Author Information & Copyright ▼
1국립암센터 비뇨기암센터
1Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea
*Corresponding Author : Jae Young Joung, MD, PhD, Department of Urology, Center for Urologic Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea, Tel: +82-31-920-1740, Fax: +82-31-920-1511, E-mail: urojy@ncc.re.kr

ⓒ Copyright 2019 Korean Society of Lymphology and Lymphedema. This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: Apr 15, 2019; Accepted: May 03, 2019

Published Online: May 31, 2019

Abatract

Lymphedema is uncommon in patients with urologic cancer, but can be associated with gross physical deformity, which severely influences patient‘s health-related quality of life. Lymphedema in patients with urologic cancer is caused by damage or obstruction of the lymphatics due to tumor involvement of the lymph nodes, surgery, radiation, or infection. Lymph node dissection is a common procedure in general surgical urology practice. Evidence has accumulated that lymph node dissection plays a role in the treatment of various urologic cancers. Particularly, lymph node dissection is considered to be associated with survival benefit in patients with advanced bladder cancer or penile cancer. In urologic oncology practice, lymphedema is a rather neglected subject, which is considered to be non-fatal. Prevention, early diagnosis, and proper treatment efforts should be made to minimize the detrimental effects of lymphedema on the patient’s quality of life.

Keywords: Lymph node excision; Lymphedema; Urologic neoplasms